A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

The Johns Hopkins-led OUtMATCH study, which enrolled clinical trial participants at 10 locations across the U.S., leads to ...

Omalizumab mechanism of action. Omalizumab binds to the Ce3 domain of immunoglobulin E (lgE) and prevents free lgE from binding to the mast cell FceRI receptor. Data courtesy of Genentech ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever ...

Among adults with chronic rhinosinusitis with nasal polyps who endured endoscopic sinus surgery, those with severe vs. mild ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Xolair (omalizumab) was approved by NICE in 2007 for treatment of severe persistent allergic asthma in adults and children over the age of 12. However, the clinical trials data submitted as ...